• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Former CDC chief Frieden to head $225m anti-heart disease initiative
Previous US Centers for Disease Control and Prevention director Dr. Tom Frieden said he will head Resolve, a new public health initiative focused on fighting heart disease and stroke which has already raised $225 million in backing from a handful of private philanthropies. The Bill & Melinda Gates Foundation, Bloomberg Philanthropies and the Chan Zuckerberg Initiative have joined in to fund the initiative. Resolve plans to invest in efforts to reduce trans-fats from restaurant menus, which follows up on Frieden’s 2006 efforts to ban trans-fats as the New York City health commissioner. The initiative will also look to...
Source: Mass Device - September 12, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Centers for Disease Control & Prevention (CDC) Source Type: news

Food as Prevention – Rising to Nutritional Challenges
Mothers and their children gather at a community nutrition centre in the little village of Rantolava, Madagascar, to learn more about a healthy diet. Credit: Alain Rakotondravony/IPSBy Gabriele RiccardiNAPLES, Italy, Nov 25 2020 (IPS) The risks factors contributing to the dramatic rise in non-communicable diseases (NCDs) in recent decades have been known for a long time but the Covid-19 pandemic has brutally exposed our collective failure to deal with them. Reporting on the findings of the latest Global Burden of Disease Study, The Lancet warns of a “perfect storm” created by the interaction of the highly infectious C...
Source: IPS Inter Press Service - Health - November 25, 2020 Category: International Medicine & Public Health Authors: Gabriele Riccardi Tags: Development & Aid Economy & Trade Featured Food Security and Nutrition Food Sustainability Global Headlines Health Humanitarian Emergencies Inequity Poverty & SDGs TerraViva United Nations Barilla Center for Food and Nutrition Foun Source Type: news